The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER) (Published September 17, 2020)
More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease (Published May 7, 2020)
Nonsense on Stilts – Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds (Published February 14, 2020)
More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes (Published February 7, 2020)
More Unnecessary Imaginary Worlds – Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis (Published January 24, 2020)
Yet Another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies (Published December 30, 2019)
ICER, ISPOR AND QALYs: A Tale of Imaginary Worlds (Published November 18, 2019)
The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies (Published October 3, 2019)
Another Rush to Judgement: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy (Published September 4, 2019)
